These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3792273)

  • 1. [Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].
    Baumann P
    Encephale; 1986; 12(4):143-8. PubMed ID: 3792273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of pharmacogenetics in psychopharmacotherapy].
    Gram LF
    Encephale; 1991; 17 Spec No 1():123-5. PubMed ID: 1864259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations.
    Tacke U; Leinonen E; Lillsunde P; Seppälä T; Arvela P; Pelkonen O; Ylitalo P
    J Clin Psychopharmacol; 1992 Aug; 12(4):262-7. PubMed ID: 1527229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of neuroleptics on debrisoquine oxidation in man.
    Syvälahti EK; Lindberg R; Kallio J; De Vocht M
    Br J Clin Pharmacol; 1986 Jul; 22(1):89-92. PubMed ID: 2874826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of antidepressant drugs: pharmacogenetics.
    Sjöqvist F; Bertilsson L
    Adv Biochem Psychopharmacol; 1984; 39():359-72. PubMed ID: 6380229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Debrisoquine hydroxylation test as an example of new possibilities of research in psychopharmacology].
    Jarema M
    Psychiatr Pol; 1995; 29(1):57-66. PubMed ID: 7878155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The use of low-dose amitriptyline in psychogeriatrics. A clinical, pharmacokinetic and pharmacogenetic study].
    Schnyder C; Baumann P; Jonzier-Perey M; Koeb L; Wertheimer J
    Schweiz Med Wochenschr; 1985 Aug; 115(33):1128-34. PubMed ID: 4035330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slow hydroxylation of tricyclic antidepressants--relationship to polymorphic drug oxidation.
    Sjöqvist F; Bertilsson L
    Prog Clin Biol Res; 1986; 214():169-88. PubMed ID: 3523507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants.
    Bertilsson L; Aberg-Wistedt A; Gustafsson LL; Nordin C
    Ther Drug Monit; 1985; 7(4):478-80. PubMed ID: 4082245
    [No Abstract]   [Full Text] [Related]  

  • 13. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.
    Baumann P; Jonzier-Perey M; Koeb L; Küpfer A; Tinguely D; Schöpf J
    Int Clin Psychopharmacol; 1986 Apr; 1(2):102-12. PubMed ID: 3571939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Debrisoquine oxidative phenotyping and psychiatric drug treatment.
    Derenne F; Joanne C; Vandel S; Bertschy G; Volmat R; Bechtel P
    Eur J Clin Pharmacol; 1989; 36(1):53-8. PubMed ID: 2563689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New aspects in research on blood levels and bioavailability of antidepressants.
    Baumann P
    Psychopathology; 1986; 19 Suppl 2():79-84. PubMed ID: 3575631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Genetic polymorphism and metabolism of tricyclic antidepressants].
    Samyn B
    Encephale; 1992; 18(6):661-4. PubMed ID: 1342665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
    Llerena A; Dorado P; Peñas-Lledó EM
    Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring in depression.
    Radziwoń-Zaleska M; Matsumoto H; Skalski M; Androsiuk W; Dziklińska A; Kunicki PK
    Pol J Pharmacol; 2000; 52(4):255-66. PubMed ID: 11345481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
    McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
    Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
    Dick B; Küpfer A; Molnàr J; Braunschweig S; Preisig R
    Schweiz Med Wochenschr; 1982 Jul; 112(30):1061-7. PubMed ID: 7123181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.